شاهد بلغة أخرى

Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

     

الأخبار

###

58,398 مشاهدات نبذة عن الشركة

  • تمت زيارة هذه الصفحة في: (آخر 7 أيام: 7) (آخر 30 يوماً: 17) (منذ نشرها: 5630) 

بيانات الشركة

    المقر الرئيسي
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • الهاتف
  • +61-3-9824-5254 
  • الفاكس
  • +61-3-9822-7735 
  • القطاع الرئيسي
  • طب وصيدلة 
  • الصناعة الرئيسية
  • Biotechnology 
  • الصفحة الرئيسية
  • www.imugene.com

وسائل الاعلام الاجتماعية